50388-51-7

Upstream product

• 4255-62-3 4,4-dimethylcyclohexane-1-one 
• 616-38-6 carbonic acid dimethyl ester 
• 1073-13-8 4,4-dimethylcyclohexenone 

Downstream Products

• 193144-62-6 1-Chloro-5,5-dimethyl-2-oxo-cyclohexanecarboxylic acid methyl ester 
• 95841-57-9 methyl 4,4-dimethylcyclopent-1-ene-1-carboxylate 
• 1256956-58-7 phenylmethyl (2R)-2-(4-hydroxy-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)pyrrolidine-1-carboxylate 
• 1027345-19-2 methyl 5,5-dimethyl-2-(trifluoromethylsulfonyloxy)cyclohex-1-enecarboxylate 
• 202931-63-3 Dimethyl 4,4-(dimethyl)cyclohexene-1,2-dicarboxylate 
• 111869-31-9 6,6-Dimethyl-2-phenyl-4,6,8,8a-tetrahydro-3aH-cyclopenta[f]isoindole-1,3-dione 
• 79618-65-8 (3aR,6aS)-3,3,5,5-Tetramethyl-6a-phenylselanyl-hexahydro-cyclopenta[c]furan-1-one 

Relevant academic research and scientific papers

Bis-Michael Acceptors as Novel Probes to Study the Keap1/Nrf2/ARE Pathway

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator that promotes the transcription of cytoprotective genes in response to oxidative/electrophilic stress. Various Michael-type compounds were designed and synthesized, and their potency

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti apoptotic protein family member.

ARYLSULFONAMIDE COMPOUNDS

The invention relates generally to small molecules that mimic the biological activity of certain peptides and proteins, to compositions containing them and to their use. In particular, the invention relates to compounds of the general formula (I) that mim

Direct catalytic asymmetric enolexo aldolizations

32 years after the first, and still the only, catalytic asymmetric intramolecular aldol reaction was published in this journal, the proline-catalyzed Hajos-Parrish-Eder-Sauer-Wiechert reaction is extended for the first time to catalytic asymmetric enolexo

Stepwise Approach toward First Generation Nonenzymatic Hydrolases

The synthesis and reactivity study of a first generation serine protease mimic is described. Central in the design stands the possibility of stabilization of the transition state by an amino triol such as 8t. En route to 8t, a series of amino alcohols (4-8) was obtained, the reactivity of which was studied toward esterification by acetylimidazole (AcIm) and by p-nitro-2,2,2-trifluoroacetanilide (PNTFA). Interesting reactivity differences were observed between the cis- and the trans-series, especially between 7c and 7t (AcIm), and between 8c and 8t (PNTFA). In both cases the results are explained by invoking extra stabilization of the tetrahedral oxyanion.

On a new synthesis of sterpurene and the bioactivity of some related Chondrostereum purpureum sesquiterpene metabolites

Sterpurene, a sesquiterpene hydrocarbon metabolite of Chondrostereum purpureum, a plant pathogen and potential mycoherbicide, was synthesized by a six-step sequence, in 33% overall yield. The key steps were a thermal [4 + 2] (Diels-Alder) cycloaddition of

ORIENTATION SPECIFIC DIELS-ALDER ADDITION OF ISOPRENE TO AN ACTIVATED 4,4-DIMETHYLCYCLOHEXENONE. AN IMPROVED ROUTE TO HIMACHALENES

Diels-Alder addition of isoprene to enone-ester 3 proceeds exclusively to the para-addition product 6.The specificity of this route constitutes a significant improvement in the previously reported total synthesis of himachalenes via 6.The mechanistic significance of the observed specificity of addition is dicussed.